MorronisideCAS# 25406-64-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 25406-64-8 | SDF | Download SDF |
PubChem ID | 11304302 | Appearance | White powder |
Formula | C17H26O11 | M.Wt | 406.38 |
Type of Compound | Iridoids | Storage | Desiccate at -20°C |
Solubility | DMSO : 125 mg/mL (307.59 mM; Need ultrasonic) H2O : 50 mg/mL (123.04 mM; Need ultrasonic) | ||
Chemical Name | methyl (1S,4aS,8S,8aS)-3-hydroxy-1-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,4a,8,8a-hexahydropyrano[3,4-c]pyran-5-carboxylate | ||
SMILES | CC1C2C(CC(O1)O)C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)OC | ||
Standard InChIKey | YTZSBJLNMIQROD-KKORFXOPSA-N | ||
Standard InChI | InChI=1S/C17H26O11/c1-6-11-7(3-10(19)26-6)8(15(23)24-2)5-25-16(11)28-17-14(22)13(21)12(20)9(4-18)27-17/h5-7,9-14,16-22H,3-4H2,1-2H3/t6-,7+,9+,10?,11+,12+,13-,14+,16-,17-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Morroniside has therapeutic effects on diabetic angiopathies, renal damage, lipid metabolism and inflammation and bone resorption. Morroniside can notably protect the brain from damage induced by focal cerebral ischemia which might be related to morroniside antioxidant and anti-apoptotic properties in the brain.Morroniside can decrease the level of cycloxygenase(Cox) and it may be the mechanism of morroniside on inhibiting the platelet aggregation induced by ADP in rabbits. |
Targets | P450 (e.g. CYP17) | Wnt/β-catenin | PI3K | Akt | MEK | ERK | COX |
In vitro | Morroniside and loganin extracted from Cornus officinalis have protective effects on rat mesangial cell proliferation exposed to advanced glycation end products by preventing oxidative stress.[Pubmed: 17487235 ]Can J Physiol Pharmacol. 2006 Dec;84(12):1267-73.Advanced glycation end products (AGE) are involved in the alterations of renal mesangial cell (MCs) growth, a feature of early stages of diabetic nephropathy (DN).
|
In vivo | Promoting neurogenesis via Wnt/β-catenin signaling pathway accounts for the neurorestorative effects of morroniside against cerebral ischemia injury.[Pubmed: 24876057]Eur J Pharmacol. 2014 Sep 5;738:214-21.Ischemic stroke is a leading cause of mortality and permanent disability in adults worldwide. Neurogenesis triggered by ischemia in the adult mammalian brain may provide insights into stroke treatment. Morroniside is an active component of sarcocarp of C. officinalis that have shown neuroprotective effects. The aim of the present study is to test whether Morroniside promotes neurogenesis via Wnt/β-catenin signaling pathway for brain recovery in a rat model of focal cerebral ischemia.
Protein kinase B and extracellular signal-regulated kinase contribute to the chondroprotective effect of morroniside on osteoarthritis chondrocytes.[Pubmed: 25754021]J Cell Mol Med. 2015 Aug;19(8):1877-86.Despite extensive studies on the multifaceted roles of Morroniside, the main active constituent of iridoid glycoside from Corni Fructus, the effect of Morroniside on osteoarthritis (OA) chondrocytes remains poorly understood.
|
Kinase Assay | Induction of CYP3A by morroniside in rats.[Pubmed: 25953268]J Pharmacol Sci. 2015 Apr;127(4):414-8.Morroniside is one of the most important iridoid glycosides in the herbal drug Cornus officinalis Sieb. et Zucc.
|
Animal Research | Effects of Morroniside on Cycloxygenase after Platelet Aggregation Induced by Adenosine Diphosphate in Rabbits.[Reference: WebLink]Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats.[Pubmed: 23546017]Morroniside improves microvascular functional integrity of the neurovascular unit after cerebral ischemia.[Pubmed: 24979385]PLoS One. 2014 Jun 30;9(6):e101194.Treating the vascular elements within the neurovascular unit is essential for protecting and repairing the brain after stroke. Acute injury on endothelial systems results in the disruption of blood-brain barrier (BBB), while post-ischemic angiogenesis plays an important role in delayed functional recovery.
Here, we considered alterations in microvessel integrity to be targets for brain recovery, and tested the natural compound Morroniside as a therapeutic approach to restore the vascular elements of injured tissue in a rat model of focal cerebral ischemia.
Mol Med Rep. 2013 May;7(5):1565-70.The aim of this study was to explore the mechanism underlying the promotive effect of Morroniside on rat mesenchymal stem cell (RMSC) proliferation and to provide an experimental basis for the development of potential new drugs.
Chinese Journal of Rehabilitation Theory & Practice, 2012, 18(4):331-2.To investigate the effect of Morroniside on cycloxygenase(Cox) in the condition of platelet aggregation induced by adenosine diphosphate(ADP) in rabbits. |
Morroniside Dilution Calculator
Morroniside Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4608 mL | 12.3038 mL | 24.6075 mL | 49.215 mL | 61.5188 mL |
5 mM | 0.4922 mL | 2.4608 mL | 4.9215 mL | 9.843 mL | 12.3038 mL |
10 mM | 0.2461 mL | 1.2304 mL | 2.4608 mL | 4.9215 mL | 6.1519 mL |
50 mM | 0.0492 mL | 0.2461 mL | 0.4922 mL | 0.9843 mL | 1.2304 mL |
100 mM | 0.0246 mL | 0.123 mL | 0.2461 mL | 0.4922 mL | 0.6152 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kanamycin Sulfate
Catalog No.:BCC1205
CAS No.:25389-94-0
- AR-C 102222
Catalog No.:BCC6092
CAS No.:253771-21-0
- TRIM
Catalog No.:BCC6847
CAS No.:25371-96-4
- Asperulosidic acid
Catalog No.:BCN3088
CAS No.:25368-11-0
- Litseglutine B
Catalog No.:BCN5120
CAS No.:25368-01-8
- 2-Amino-6-methylbenzothiazole
Catalog No.:BCC8543
CAS No.:2536-91-6
- 16-O-Acetylpolyporenic acid C
Catalog No.:BCN4058
CAS No.:2535-06-0
- Wiskostatin
Catalog No.:BCC7934
CAS No.:253449-04-6
- (+)-Corlumidine
Catalog No.:BCN2662
CAS No.:25344-54-1
- Viniferin
Catalog No.:BCN3757
CAS No.:253435-07-3
- Trazodone HCl
Catalog No.:BCC5032
CAS No.:25332-39-2
- BMS 195614
Catalog No.:BCC7740
CAS No.:253310-42-8
- Boc-ß-HoAsp(OBzl)-OH
Catalog No.:BCC3229
CAS No.:254101-10-5
- Phellopterin
Catalog No.:BCN2637
CAS No.:2543-94-4
- H-Cys(pMeOBzl)-OH
Catalog No.:BCC2909
CAS No.:2544-31-2
- Dehydropitavastatin ethyl ester
Catalog No.:BCC8931
CAS No.:254452-91-0
- (+)-Afzelechin
Catalog No.:BCN5121
CAS No.:2545-00-8
- Felbamate
Catalog No.:BCC4904
CAS No.:25451-15-4
- H-D-Glu-OtBu
Catalog No.:BCC2938
CAS No.:25456-76-2
- H-Asn-OtBu
Catalog No.:BCC2877
CAS No.:25456-86-4
- Demethyleneberberine
Catalog No.:BCN2829
CAS No.:25459-91-0
- 2-MPPA
Catalog No.:BCC7995
CAS No.:254737-29-6
- Emricasan
Catalog No.:BCC5367
CAS No.:254750-02-2
- Talsupram hydrochloride
Catalog No.:BCC7924
CAS No.:25487-28-9
Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats.[Pubmed:23546017]
Mol Med Rep. 2013 May;7(5):1565-70.
The aim of this study was to explore the mechanism underlying the promotive effect of Morroniside on rat mesenchymal stem cell (RMSC) proliferation and to provide an experimental basis for the development of potential new drugs. RMSCs were obtained from the bone marrow of Sprague-Dawley rats aged 3-4 months. The proliferation of primary and subcultured RMSCs in the high, medium and lowconcentration Morroniside intervention and blank control groups was observed using light microscopy. Cell proliferation and survival conditions were detected using methyl thiazolyl tetrazolium (MTT) colorimetric tests. Light microscopy and the MTT assay revealed that RMSC adherence time in the Morroniside groups was shorter compared with that of the control group. Twelve hours after the media of primary RMSCs were changed, the number of adherent cells in the Morroniside groups increased and an elongated cell morphology was observed. The cells at the fourth passage in the Morroniside groups fused completely 1216 h after inoculation and then rapidly entered into the logarithmic phase. The primary RMSCs of the Morroniside intervention groups grew into typical bone marrow mesenchymal stem cell (BMSC) colonies after 4 days of Morroniside treatment and their fusion rate had reached 80% after 911 days. By contrast, the cell fusion rate of the control group only reached 75-80% after 14 days of Morroniside treatment. Morroniside exhibited a similar promotive effect on proliferation in primary and subcultured RMSCs. Morroniside may promote RMSC proliferation through secreted factors, cell-to-cell interactions and/or the interactions between cellular adhesion molecules and extracellular matrices (ECMs). However, the specific mechanism underlying this effect remains to be fully elucidated.
Morroniside improves microvascular functional integrity of the neurovascular unit after cerebral ischemia.[Pubmed:24979385]
PLoS One. 2014 Jun 30;9(6):e101194.
Treating the vascular elements within the neurovascular unit is essential for protecting and repairing the brain after stroke. Acute injury on endothelial systems results in the disruption of blood-brain barrier (BBB), while post-ischemic angiogenesis plays an important role in delayed functional recovery. Here, we considered alterations in microvessel integrity to be targets for brain recovery, and tested the natural compound Morroniside as a therapeutic approach to restore the vascular elements of injured tissue in a rat model of focal cerebral ischemia. Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) model, and Morroniside was then administered intragastrically once a day at doses of 30, 90, and 270 mg/kg. BBB integrity and associated factors were analyzed to identify cerebrovascular permeability 3 days after MCAO. The recruitment of endothelial progenitor cells (EPCs), the expression of angiogenic factors and the new vessel formation in the peri-infarct cortex of rats were examined 7 days after MCAO to identify the angiogenesis. We demonstrated that at 3 days post-ischemia, Morroniside preserved neurovascular unit function by ameliorating BBB injury. By 7 days post-ischemia, Morroniside amplified angiogenesis, in part by enhancing endothelial progenitor cell proliferation and expression of angiogenic factors. Morever, the increase in the amount of vWF+ vessels induced by ischemia could be extended to 28 days after administration of Morroniside, indicating the crucial role of Morroniside in angiogenesis during the chronic phase. Taken together, our findings suggested that Morroniside might offer a novel therapeutic approach for promoting microvascular integrity recovery and provide a thoroughly new direction for stroke therapy.
Promoting neurogenesis via Wnt/beta-catenin signaling pathway accounts for the neurorestorative effects of morroniside against cerebral ischemia injury.[Pubmed:24876057]
Eur J Pharmacol. 2014 Sep 5;738:214-21.
Ischemic stroke is a leading cause of mortality and permanent disability in adults worldwide. Neurogenesis triggered by ischemia in the adult mammalian brain may provide insights into stroke treatment. Morroniside is an active component of sarcocarp of C. officinalis that have shown neuroprotective effects. The aim of the present study is to test whether Morroniside promotes neurogenesis via Wnt/beta-catenin signaling pathway for brain recovery in a rat model of focal cerebral ischemia. Morroniside was administered intragastrically once daily at the concentrations of 30, 90 and 270 mg/kg for 7 days post-ischemia. Neurological functions were detected by Ludmila Belayev score tests. Endogenous neural stem cells responses were investigated with immunofluorescence staining of Ki-67 and Nestin to identify the neurogenesis in the subventricular zone (SVZ). The expression of proteins involved in and related to Wnt/beta-catenin signaling pathway was detected by western blotting analysis. Morroniside significantly promoted neurogenesis for brain recovery 7 days post-ischemia. Increased expression of Wnt 3a, beta-catenin and T-cell transcription factor-4 (Tcf-4), along with activation of downstream transcription factors Pax6 and neurogenin2 (Ngn2), indicated that the neurorestorative effects of Morroniside may be associated with Wnt/beta-catenin signaling pathway. These data provide support for understanding the mechanisms of Morroniside in neurorestorative effects and suggest a potential new strategy for ischemic stroke treatment.
Morroniside and loganin extracted from Cornus officinalis have protective effects on rat mesangial cell proliferation exposed to advanced glycation end products by preventing oxidative stress.[Pubmed:17487235]
Can J Physiol Pharmacol. 2006 Dec;84(12):1267-73.
Advanced glycation end products (AGE) are involved in the alterations of renal mesangial cell (MCs) growth, a feature of early stages of diabetic nephropathy (DN). We postulate that Morroniside and loganin, 2 components extracted from Cornus officinalis, may ameliorate the detrimental effects of AGE-induced MCs proliferation by preventing oxidative stress. Rat MCs cultured in AGE milieu were treated with Morroniside and loganin. Results showed that Morroniside and loganin inhibited AGE-induced MC proliferation as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Fluorescence microscopy revealed that the Morroniside and loganin improved the morphological changes of MCs. Flow cytometric analysis showed that Morroniside and loganin inhibited the cell cycle of rat MCs. Furthermore, the level of reactive oxygen species was significantly reduced, and the activities of superoxide dismutase and glutathione peroxidase were markedly increased, whereas the level of malondialdehyde was not significantly reduced. These results suggest that Morroniside and loganin regulate MC growth by preventing oxidative stress. Thus, this study provides a molecular basis for the use of Morroniside and loganin in the early stages of DN.
Induction of CYP3A by morroniside in rats.[Pubmed:25953268]
J Pharmacol Sci. 2015 Apr;127(4):414-8.
Morroniside is one of the most important iridoid glycosides in the herbal drug Cornus officinalis Sieb. et Zucc. The current study was designed to investigate the ex vivo and in vivo effects of Morroniside on CYP3A activity in rats after treatment with Morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.). Morroniside was found to induce CYP3A. According to the ex vivo experiment, the activity of CYP3A was measured by the quantification of 1-hydroxymidazolam, which was the metabolite from CYP3A probe substrate, midazolam. The concentration of 1-hydroxymidazolam was determined by using a validated liquid chromatography coupled with tandem mass spectrometry detection (LC-MS/MS) method. The levels of messenger RNA (mRNA) and protein of CYP3A were determined by reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting analysis, respectively. The pharmacokinetics of midazolam in rats after treatment with Morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.) were investigated in vivo. After treatment with Morroniside, the activity, mRNA and protein expression of CYP3A were significantly induced and the absorbance and bioavailability of midazolam in rats were reduced. The results indicated that Morroniside could induce the activity of CYP3A.
Protein kinase B and extracellular signal-regulated kinase contribute to the chondroprotective effect of morroniside on osteoarthritis chondrocytes.[Pubmed:25754021]
J Cell Mol Med. 2015 Aug;19(8):1877-86.
Despite extensive studies on the multifaceted roles of Morroniside, the main active constituent of iridoid glycoside from Corni Fructus, the effect of Morroniside on osteoarthritis (OA) chondrocytes remains poorly understood. Here, we investigated the influence of Morroniside on cultured human OA chondrocytes and a rat experimental model of OA. The results showed that Morroniside enhanced the cell viability and the levels of proliferating cell nuclear antigen expression (PCNA), type II collagen and aggrecan in human OA chondrocytes, indicating that Morroniside promoted chondrocyte survival and matrix synthesis. Furthermore, different doses of Morroniside activated protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) in human OA chondrocytes, and in turn, triggered AKT/S6 and ERK/P70S6K/S6 pathway, respectively. The PI3K/AKT inhibitor LY294002 or the MEK/ERK inhibitor U0126 attenuated the effect of Morroniside on human OA chondrocytes, indicating that the activation of AKT and ERK contributed to the regulation of Morroniside in human OA chondrocytes. In addition, the intra-articular injection of Morroniside elevated the level of proteoglycans in cartilage matrix and the thickness of articular cartilage in a rat experimental model of OA, with the increase of AKT and ERK activation. As a consequence, Morroniside has chondroprotective effect on OA chondrocytes, and may have the therapeutic potential for OA treatment.